Laurus Labs Limited
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadershipposition in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial…
What Laurus files
- Others45
- Investor Meet40
- Important25
- Updates23
- PPTs8
- Board Meeting7
Laurus Labs Limited will participate in an in-person group investor meeting organized by ICICI Securities in Hyderabad. Management has clarified that no unpublished price sensitive information will be shared during this interaction.
Laurus Labs will participate in an in-person group meeting at the Antique Pharma Investor Day in Hyderabad on September 7, 2026. No price-sensitive information will be shared.
Laurus Labs received an independent ESG score of 63/100 for FY26 from NSE Sustainability. This highlights its environmental, social, and governance performance for investors.
Laurus Labs reported strong Q1 FY27 results with revenues at INR 2,026 Cr (+29% YoY), EBITDA at INR 644 Cr (31.8% margin), and PAT at INR 368 Cr. CDMO business surged 69% to INR 835 Cr, with 55% from commercial supplies. Affordable Medicines grew 10% to INR 1,156 Cr. Management...
Laurus Labs allotted 62,635 equity shares to employees via ESOPs, raising Rs. 2.90 Cr. This increases the total paid-up capital to Rs. 1080.62 Cr, bringing new shares into circulation.